88 results about "Kidney fibrosis" patented technology

The invention belongs to the technical field of traditional Chinese medicine sustained-release preparations, in particular to a water-soluble effective component containing centella asiatica for treating trauma, surgical trauma, burns, keloids and scleroderma, antidepressant and treating liver and kidney fibrosis. Centella glycosides) traditional Chinese medicine slow-release preparation and preparation method thereof. The invention adopts the modern preparation technology to compress the traditional Chinese medicine slow-release preparation with solid medicine, skeleton-type auxiliary materials and other excipients. The solid drug refers to the total glycosides of the water-soluble extract of the traditional Chinese medicine Centella asiatica. The total glycosides contain madecassoside and centella asiatica. The total glycosides content in the extract should not be less than 60%. Skeleton-type excipients mainly refer to hydroxypropyl methylcellulose. By adjusting the amount of excipients in the prescription, the release rate of asiaticoside can be controlled, so as to stabilize the blood concentration of the drug, reduce the frequency of medication, and facilitate the use of patients.

<heading lvl="1">SUMMARY OF THE INVENTION < / heading> The use of gene therapy for the treatment of different kinds of fibrosis in human beings is disclosed. The purpose is the use of "therapeutic2 genes specifically directed to target organs to revert and / or prevent the development of the fibrosis process. The potential application of gene therapy to patients with fibrosis and / or cirrhosis will depend to a large extent on the successful delivery of genes which encode for therapeutic proteins to livers with severe fibrosis and that these genes which encode for proteins human MMP-8 active and latent, MMP-1, MMP-2, MMP-9 and MMP-13; human uPA wild type and / or modified (or its truncated version), the truncated receptor for TGF-beta type II and Smad-7 can be directed by adenovirus and / or other recombinant vectors that cannot transduce (infect) others organs. The recombinant adenoviruses (AdR) are vectors highly efficient for the transduction of therapeutic genes to diverse target cells. We have proved that they can carry genes to cirrhotic livers. The delivery of therapeutic genes through such adenoviral vectors and other recombinant vectors could also be performed using cationic and anionic liposomes (DOTMA). Therefore, we propose the use of this patent to be applied in the same manner to: Renal fibrosis Pulmonary fibrosis Hypertrophic and keloid scars (skin fibrosis), and Other kinds of fibrosis.

The invention discloses a traditional Chinese medicine for treating hypertension early-stage kidney damage and a preparation method thereof. The traditional Chinese medicine for treating hypertension early-stage kidney damage disclosed by the invention mainly comprises radix rehmanniae preparata, fructus corni, yam, cortex eucommiae, radix salviae miltiorrhizae and tortoise shell, and is preparedinto various common preparations by the traditional technology of traditional Chinese medicine. The traditional Chinese medicine for treating hypertension early-stage kidney damage disclosed by the invention can effectively relieve the kidney fibrosis progress of the patient suffering hypertension early-stage kidney damage, reduces the kidney burden of the patient, and effectively controls the disease progression; in combination with the oral hypotensor benazepril, a synergistic effect is realized for the blood pressure reducing effect; and compared with the oral hypotensor benazepril only, the traditional Chinese medicine disclosed by the invention takes effect quickly in reducing blood pressure, and the final blood pressure reducing effect is better. Compared with the prior art, the invention has outstanding substantial characteristics and obvious progress.

The invention discloses an application of a compound inhibiting dynein light chain roadblock-type 2 in preparation of a medicine treating kidney diseases especially kidney failure diabetes. A knockdown dynein light chain roadblock-type 2 plasmid is used for preparing the medicine. A medicine for treating diabetic nephropathy is also disclosed and comprises the knockdown dynein light chain roadblock-type 2 plasmid. The medicine can be used for achieving novel, safe, effective and controllable gene therapy methods and for inhibiting TGF-beta mediated kidney fibrosis.

The invention provides the application of rosmarinic acid for preparing medicine that treats or prevents liver and kidney fibrosis. The medicine can be oral liquid or injection, and the dosage for injection is 50 -1500mg, and for oral liquid is 100-3000mg.

Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.

The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to O-(tetrahydropyrrolyl)ethyl derivatives of cleistanone, a preparation method and an application thereof in the preparation of drugs for preventing or treating renal fibrosis. The present invention synthesizes a new O-(tetrahydropyrrolyl) ethyl derivative of Cleistanone, and discloses its preparation method. Pharmacological experiments show that the O-(tetrahydropyrrolyl)ethyl derivatives of Cleistanone of the present invention have the effect of preventing or treating renal fibrosis, and have the value of developing drugs for preventing or treating renal fibrosis.

The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.